LPGO — Lipigon Pharmaceuticals AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK1.64m
- -SEK8.58m
Annual cashflow statement for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.2 | -37.7 | -12.4 | -25.6 | -32.2 |
| Depreciation | |||||
| Non-Cash Items | -0.243 | -0.023 | 0.093 | -0.283 | -0.026 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.11 | 0.274 | -2.05 | 1.02 | -3.61 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -70.6 | -74.9 | -28.6 | -49.6 | -71.5 |
| Capital Expenditures | -0.119 | 0 | — | -0.235 | -0.108 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.238 | 0 | — | -0.47 | -0.216 |
| Financing Cash Flow Items | -5.22 | -3.99 | -6.56 | -0.26 | -6.68 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 102 | 37.2 | 73.4 | 9.16 | 68.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 15.9 | -18.8 | 22.3 | -20.2 | -1.56 |